Free Trial

OptiNose Q3 2023 Earnings Report

OptiNose logo
$9.10 -0.04 (-0.44%)
As of 04/4/2025 04:00 PM Eastern

OptiNose EPS Results

Actual EPS
-$1.20
Consensus EPS
-$1.50
Beat/Miss
Beat by +$0.30
One Year Ago EPS
N/A

OptiNose Revenue Results

Actual Revenue
$19.82 million
Expected Revenue
$17.80 million
Beat/Miss
Beat by +$2.02 million
YoY Revenue Growth
N/A

OptiNose Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

OptiNose Earnings Headlines

Optinose reports Q4 EPS (3c) vs ($1.33) last year
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Optinose downgraded to Neutral from Buy at H.C. Wainwright
See More OptiNose Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiNose? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiNose and other key companies, straight to your email.

About OptiNose

OptiNose (NASDAQ:OPTN), a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

View OptiNose Profile

More Earnings Resources from MarketBeat